BTK inhibitors are able to interfere with cell signaling cascades and prevent key phosphorylations in B cells, therefore preventing or reducing inflammation.
The “Bruton Tyrosine Kinase (BTK) Inhibitors Industry Forecast” looks at past sales and reviews total world Bruton Tyrosine Kinase (BTK) Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Bruton Tyrosine Kinase (BTK) Inhibitors sales for 2023 through 2029. With Bruton Tyrosine Kinase (BTK) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bruton Tyrosine Kinase (BTK) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Bruton Tyrosine Kinase (BTK) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bruton Tyrosine Kinase (BTK) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bruton Tyrosine Kinase (BTK) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bruton Tyrosine Kinase (BTK) Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bruton Tyrosine Kinase (BTK) Inhibitors.
The global Bruton Tyrosine Kinase (BTK) Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bruton Tyrosine Kinase (BTK) Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bruton Tyrosine Kinase (BTK) Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bruton Tyrosine Kinase (BTK) Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bruton Tyrosine Kinase (BTK) Inhibitors players cover Johnson & Johnson and AbbVie (Imbruvica), AstraZeneca (Calquence), BeiGene (Zanubrutinib), InnoCare (Orelabrutinib) and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bruton Tyrosine Kinase (BTK) Inhibitors market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
First Generation
Second Generation
Segmentation by application
Leukemia
Lymphoma
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson and AbbVie (Imbruvica)
AstraZeneca (Calquence)
BeiGene (Zanubrutinib)
InnoCare (Orelabrutinib)
Merck
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bruton Tyrosine Kinase (BTK) Inhibitors market?
What factors are driving Bruton Tyrosine Kinase (BTK) Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bruton Tyrosine Kinase (BTK) Inhibitors market opportunities vary by end market size?
How does Bruton Tyrosine Kinase (BTK) Inhibitors break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Bruton Tyrosine Kinase (BTK) Inhibitors by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Bruton Tyrosine Kinase (BTK) Inhibitors by Country/Region, 2018, 2022 & 2029
2.2 Bruton Tyrosine Kinase (BTK) Inhibitors Segment by Type
2.2.1 First Generation
2.2.2 Second Generation
2.3 Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Type
2.3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sales Market Share by Type (2018-2023)
2.3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Revenue and Market Share by Type (2018-2023)
2.3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sale Price by Type (2018-2023)
2.4 Bruton Tyrosine Kinase (BTK) Inhibitors Segment by Application
2.4.1 Leukemia
2.4.2 Lymphoma
2.4.3 Others
2.5 Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Application
2.5.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sale Market Share by Application (2018-2023)
2.5.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Revenue and Market Share by Application (2018-2023)
2.5.3 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sale Price by Application (2018-2023)
3 Global Bruton Tyrosine Kinase (BTK) Inhibitors by Company
3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Breakdown Data by Company
3.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Sales by Company (2018-2023)
3.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sales Market Share by Company (2018-2023)
3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Revenue by Company (2018-2023)
3.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Revenue by Company (2018-2023)
3.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Company (2018-2023)
3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitors Sale Price by Company
3.4 Key Manufacturers Bruton Tyrosine Kinase (BTK) Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bruton Tyrosine Kinase (BTK) Inhibitors Product Location Distribution
3.4.2 Players Bruton Tyrosine Kinase (BTK) Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Bruton Tyrosine Kinase (BTK) Inhibitors by Geographic Region
4.1 World Historic Bruton Tyrosine Kinase (BTK) Inhibitors Market Size by Geographic Region (2018-2023)
4.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Bruton Tyrosine Kinase (BTK) Inhibitors Market Size by Country/Region (2018-2023)
4.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Sales by Country/Region (2018-2023)
4.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Revenue by Country/Region (2018-2023)
4.3 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Sales Growth
4.4 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Sales Growth
4.5 Europe Bruton Tyrosine Kinase (BTK) Inhibitors Sales Growth
4.6 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Sales Growth
5 Americas
5.1 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Country
5.1.1 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Country (2018-2023)
5.1.2 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Revenue by Country (2018-2023)
5.2 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Type
5.3 Americas Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Region
6.1.1 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Region (2018-2023)
6.1.2 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Revenue by Region (2018-2023)
6.2 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Type
6.3 APAC Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitors by Country
7.1.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Country (2018-2023)
7.1.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitors Revenue by Country (2018-2023)
7.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Type
7.3 Europe Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors by Country
8.1.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Country (2018-2023)
8.1.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Revenue by Country (2018-2023)
8.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Type
8.3 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bruton Tyrosine Kinase (BTK) Inhibitors
10.3 Manufacturing Process Analysis of Bruton Tyrosine Kinase (BTK) Inhibitors
10.4 Industry Chain Structure of Bruton Tyrosine Kinase (BTK) Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bruton Tyrosine Kinase (BTK) Inhibitors Distributors
11.3 Bruton Tyrosine Kinase (BTK) Inhibitors Customer
12 World Forecast Review for Bruton Tyrosine Kinase (BTK) Inhibitors by Geographic Region
12.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Size Forecast by Region
12.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitors Forecast by Region (2024-2029)
12.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitors Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Bruton Tyrosine Kinase (BTK) Inhibitors Forecast by Type
12.7 Global Bruton Tyrosine Kinase (BTK) Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Johnson & Johnson and AbbVie (Imbruvica)
13.1.1 Johnson & Johnson and AbbVie (Imbruvica) Company Information
13.1.2 Johnson & Johnson and AbbVie (Imbruvica) Bruton Tyrosine Kinase (BTK) Inhibitors Product Portfolios and Specifications
13.1.3 Johnson & Johnson and AbbVie (Imbruvica) Bruton Tyrosine Kinase (BTK) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Johnson & Johnson and AbbVie (Imbruvica) Main Business Overview
13.1.5 Johnson & Johnson and AbbVie (Imbruvica) Latest Developments
13.2 AstraZeneca (Calquence)
13.2.1 AstraZeneca (Calquence) Company Information
13.2.2 AstraZeneca (Calquence) Bruton Tyrosine Kinase (BTK) Inhibitors Product Portfolios and Specifications
13.2.3 AstraZeneca (Calquence) Bruton Tyrosine Kinase (BTK) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca (Calquence) Main Business Overview
13.2.5 AstraZeneca (Calquence) Latest Developments
13.3 BeiGene (Zanubrutinib)
13.3.1 BeiGene (Zanubrutinib) Company Information
13.3.2 BeiGene (Zanubrutinib) Bruton Tyrosine Kinase (BTK) Inhibitors Product Portfolios and Specifications
13.3.3 BeiGene (Zanubrutinib) Bruton Tyrosine Kinase (BTK) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BeiGene (Zanubrutinib) Main Business Overview
13.3.5 BeiGene (Zanubrutinib) Latest Developments
13.4 InnoCare (Orelabrutinib)
13.4.1 InnoCare (Orelabrutinib) Company Information
13.4.2 InnoCare (Orelabrutinib) Bruton Tyrosine Kinase (BTK) Inhibitors Product Portfolios and Specifications
13.4.3 InnoCare (Orelabrutinib) Bruton Tyrosine Kinase (BTK) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 InnoCare (Orelabrutinib) Main Business Overview
13.4.5 InnoCare (Orelabrutinib) Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Bruton Tyrosine Kinase (BTK) Inhibitors Product Portfolios and Specifications
13.5.3 Merck Bruton Tyrosine Kinase (BTK) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
14 Research Findings and Conclusion
*If Applicable.